Cargando…

Ethical considerations in deploying triple artemisinin-based combination therapies for malaria: An analysis of stakeholders’ perspectives in Burkina Faso and Nigeria

BACKGROUND: Artemisinin-based combination therapies (ACTs) are the recommended treatment for uncomplicated Plasmodium falciparum malaria in all malaria endemic countries. Artemisinin resistance, partner drug resistance, and subsequent ACT failure are widespread in Southeast Asia. The more recent ind...

Descripción completa

Detalles Bibliográficos
Autores principales: Tindana, Paulina, Guissou, Rosemonde, Bolarinwa, Oladimeji Akeem, Tou, Fatoumata, de Haan, Freek, Dhorda, Mehul, Dondorp, Arjen M., Amaratunga, Chanaki, Mokuolu, Olugbenga Ayodeji, Ouedraogo, Jean Bosco, Cheah, Phaik Yeong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9462557/
https://www.ncbi.nlm.nih.gov/pubmed/36083995
http://dx.doi.org/10.1371/journal.pone.0273249
_version_ 1784787212169117696
author Tindana, Paulina
Guissou, Rosemonde
Bolarinwa, Oladimeji Akeem
Tou, Fatoumata
de Haan, Freek
Dhorda, Mehul
Dondorp, Arjen M.
Amaratunga, Chanaki
Mokuolu, Olugbenga Ayodeji
Ouedraogo, Jean Bosco
Cheah, Phaik Yeong
author_facet Tindana, Paulina
Guissou, Rosemonde
Bolarinwa, Oladimeji Akeem
Tou, Fatoumata
de Haan, Freek
Dhorda, Mehul
Dondorp, Arjen M.
Amaratunga, Chanaki
Mokuolu, Olugbenga Ayodeji
Ouedraogo, Jean Bosco
Cheah, Phaik Yeong
author_sort Tindana, Paulina
collection PubMed
description BACKGROUND: Artemisinin-based combination therapies (ACTs) are the recommended treatment for uncomplicated Plasmodium falciparum malaria in all malaria endemic countries. Artemisinin resistance, partner drug resistance, and subsequent ACT failure are widespread in Southeast Asia. The more recent independent emergence of artemisinin resistance in Africa is alarming. In response, triple artemisinin-based combination therapies (TACTs) are being developed to mitigate the risks associated with increasing drug resistance. Since ACTs are still effective in Africa, where malaria is mainly a paediatric disease, the potential deployment of TACTs raises important ethical questions. This paper presents an analysis of stakeholders’ perspectives regarding key ethical considerations to be considered in the deployment of TACTs in Africa provided they are found to be safe, well-tolerated and effective for the treatment of uncomplicated malaria. METHODS: We conducted a qualitative study in Burkina Faso and Nigeria assessing stakeholders’ (policy makers, suppliers and end-users) perspectives on ethical issues regarding the potential future deployment of TACTs through 68 in-depth interviews and 11 focus group discussions. FINDINGS: Some respondents suggested that there should be evidence of local artemisinin resistance before they consider deploying TACTs, while others suggested that TACTs should be deployed to protect the efficacy of current ACTs. Respondents suggested that additional side effects of TACTs compared to ACTs should be minimal and the cost of TACTs to end-users should not be higher than the cost of current ACTs. There was some disagreement among respondents regarding whether patients should have a choice of treatment options between ACTs and TACTs or only have TACTs available, while ACTs are still effective. The study also suggests that community, public and stakeholder engagement activities are essential to support the introduction and effective uptake of TACTs. CONCLUSION: Addressing ethical issues regarding TACTs and engaging early with stakeholders will be important for their potential deployment in Africa.
format Online
Article
Text
id pubmed-9462557
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-94625572022-09-10 Ethical considerations in deploying triple artemisinin-based combination therapies for malaria: An analysis of stakeholders’ perspectives in Burkina Faso and Nigeria Tindana, Paulina Guissou, Rosemonde Bolarinwa, Oladimeji Akeem Tou, Fatoumata de Haan, Freek Dhorda, Mehul Dondorp, Arjen M. Amaratunga, Chanaki Mokuolu, Olugbenga Ayodeji Ouedraogo, Jean Bosco Cheah, Phaik Yeong PLoS One Research Article BACKGROUND: Artemisinin-based combination therapies (ACTs) are the recommended treatment for uncomplicated Plasmodium falciparum malaria in all malaria endemic countries. Artemisinin resistance, partner drug resistance, and subsequent ACT failure are widespread in Southeast Asia. The more recent independent emergence of artemisinin resistance in Africa is alarming. In response, triple artemisinin-based combination therapies (TACTs) are being developed to mitigate the risks associated with increasing drug resistance. Since ACTs are still effective in Africa, where malaria is mainly a paediatric disease, the potential deployment of TACTs raises important ethical questions. This paper presents an analysis of stakeholders’ perspectives regarding key ethical considerations to be considered in the deployment of TACTs in Africa provided they are found to be safe, well-tolerated and effective for the treatment of uncomplicated malaria. METHODS: We conducted a qualitative study in Burkina Faso and Nigeria assessing stakeholders’ (policy makers, suppliers and end-users) perspectives on ethical issues regarding the potential future deployment of TACTs through 68 in-depth interviews and 11 focus group discussions. FINDINGS: Some respondents suggested that there should be evidence of local artemisinin resistance before they consider deploying TACTs, while others suggested that TACTs should be deployed to protect the efficacy of current ACTs. Respondents suggested that additional side effects of TACTs compared to ACTs should be minimal and the cost of TACTs to end-users should not be higher than the cost of current ACTs. There was some disagreement among respondents regarding whether patients should have a choice of treatment options between ACTs and TACTs or only have TACTs available, while ACTs are still effective. The study also suggests that community, public and stakeholder engagement activities are essential to support the introduction and effective uptake of TACTs. CONCLUSION: Addressing ethical issues regarding TACTs and engaging early with stakeholders will be important for their potential deployment in Africa. Public Library of Science 2022-09-09 /pmc/articles/PMC9462557/ /pubmed/36083995 http://dx.doi.org/10.1371/journal.pone.0273249 Text en © 2022 Tindana et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Tindana, Paulina
Guissou, Rosemonde
Bolarinwa, Oladimeji Akeem
Tou, Fatoumata
de Haan, Freek
Dhorda, Mehul
Dondorp, Arjen M.
Amaratunga, Chanaki
Mokuolu, Olugbenga Ayodeji
Ouedraogo, Jean Bosco
Cheah, Phaik Yeong
Ethical considerations in deploying triple artemisinin-based combination therapies for malaria: An analysis of stakeholders’ perspectives in Burkina Faso and Nigeria
title Ethical considerations in deploying triple artemisinin-based combination therapies for malaria: An analysis of stakeholders’ perspectives in Burkina Faso and Nigeria
title_full Ethical considerations in deploying triple artemisinin-based combination therapies for malaria: An analysis of stakeholders’ perspectives in Burkina Faso and Nigeria
title_fullStr Ethical considerations in deploying triple artemisinin-based combination therapies for malaria: An analysis of stakeholders’ perspectives in Burkina Faso and Nigeria
title_full_unstemmed Ethical considerations in deploying triple artemisinin-based combination therapies for malaria: An analysis of stakeholders’ perspectives in Burkina Faso and Nigeria
title_short Ethical considerations in deploying triple artemisinin-based combination therapies for malaria: An analysis of stakeholders’ perspectives in Burkina Faso and Nigeria
title_sort ethical considerations in deploying triple artemisinin-based combination therapies for malaria: an analysis of stakeholders’ perspectives in burkina faso and nigeria
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9462557/
https://www.ncbi.nlm.nih.gov/pubmed/36083995
http://dx.doi.org/10.1371/journal.pone.0273249
work_keys_str_mv AT tindanapaulina ethicalconsiderationsindeployingtripleartemisininbasedcombinationtherapiesformalariaananalysisofstakeholdersperspectivesinburkinafasoandnigeria
AT guissourosemonde ethicalconsiderationsindeployingtripleartemisininbasedcombinationtherapiesformalariaananalysisofstakeholdersperspectivesinburkinafasoandnigeria
AT bolarinwaoladimejiakeem ethicalconsiderationsindeployingtripleartemisininbasedcombinationtherapiesformalariaananalysisofstakeholdersperspectivesinburkinafasoandnigeria
AT toufatoumata ethicalconsiderationsindeployingtripleartemisininbasedcombinationtherapiesformalariaananalysisofstakeholdersperspectivesinburkinafasoandnigeria
AT dehaanfreek ethicalconsiderationsindeployingtripleartemisininbasedcombinationtherapiesformalariaananalysisofstakeholdersperspectivesinburkinafasoandnigeria
AT dhordamehul ethicalconsiderationsindeployingtripleartemisininbasedcombinationtherapiesformalariaananalysisofstakeholdersperspectivesinburkinafasoandnigeria
AT dondorparjenm ethicalconsiderationsindeployingtripleartemisininbasedcombinationtherapiesformalariaananalysisofstakeholdersperspectivesinburkinafasoandnigeria
AT amaratungachanaki ethicalconsiderationsindeployingtripleartemisininbasedcombinationtherapiesformalariaananalysisofstakeholdersperspectivesinburkinafasoandnigeria
AT mokuoluolugbengaayodeji ethicalconsiderationsindeployingtripleartemisininbasedcombinationtherapiesformalariaananalysisofstakeholdersperspectivesinburkinafasoandnigeria
AT ouedraogojeanbosco ethicalconsiderationsindeployingtripleartemisininbasedcombinationtherapiesformalariaananalysisofstakeholdersperspectivesinburkinafasoandnigeria
AT cheahphaikyeong ethicalconsiderationsindeployingtripleartemisininbasedcombinationtherapiesformalariaananalysisofstakeholdersperspectivesinburkinafasoandnigeria